Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

884 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Bardelmeijer HA, Ouwehand M, Malingré MM, Schellens J, Beijnen JH, van Tellingen O. Bardelmeijer HA, et al. Among authors: schellens j. Cancer Chemother Pharmacol. 2002 Feb;49(2):119-25. doi: 10.1007/s00280-001-0394-2. Epub 2001 Nov 20. Cancer Chemother Pharmacol. 2002. PMID: 11862425
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
van Kesteren C, Twelves C, Bowman A, Hoekman K, López-Lázaro L, Jimeno J, Guzman C, Mathôt RA, Simpson A, Vermorken JB, Smyth J, Schellens JH, Hillebrand MJ, Rosing H, Beijnen JH. van Kesteren C, et al. Among authors: schellens jh. Anticancer Drugs. 2002 Apr;13(4):381-93. doi: 10.1097/00001813-200204000-00007. Anticancer Drugs. 2002. PMID: 11984084 Clinical Trial.
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Schellens JH, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR. Schellens JH, et al. Invest New Drugs. 2002 Feb;20(1):83-93. doi: 10.1023/a:1014454821885. Invest New Drugs. 2002. PMID: 12003197 Clinical Trial.
884 results